Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth

Eli Lilly's Q1 2025 performance was primarily driven by its GLP-1 blockbusters, Mounjaro and Zepbound, which constituted 48% of sales, yet its non-obesity portfolio, including oncology drug Verzenio (+10% YoY) and immunology drug Taltz (+26% YoY), is increasingly contributing to top-line growth and strategic diversification. This strategy aligns with a broader industry trend, as major pharmaceutical peers like AbbVie and Merck also actively expand their therapeutic pipelines to mitigate dependence on core flagship products. Despite strong growth drivers and upcoming launches, LLY shares trade at a premium 29.45x forward P/E, significantly above the industry average, and the company currently holds a Zacks Rank #4 (Sell), suggesting a cautious outlook on its valuation.

Analysis

Eli Lilly's financial profile is dominated by its GLP-1 franchise, with Mounjaro and Zepbound accounting for 48% of total sales in the first quarter of 2025. However, the company is demonstrating successful diversification, with its non-obesity portfolio showing robust growth. Key contributors include the oncology drug Verzenio, which grew 10% year-over-year to comprise 9% of sales, and the immunology drug Taltz, which grew 26% to represent 6% of sales. This strategy mirrors a broader industry trend, with peers like AbbVie and Merck also expanding beyond their flagship products to mitigate concentration risk. Despite this strong operational performance and a pipeline that includes the potential 2025 launch of imlunestrant, significant valuation concerns persist. The stock trades at a 29.45x forward P/E ratio, a steep premium to the industry average of 15.04, although this is below its five-year mean of 34.54. This rich valuation is coupled with cautionary signals, including a slight decline in 2025 EPS estimates over the past 60 days and a Zacks Rank of #4 (Sell), indicating that near-term expectations may be overly optimistic.

Key Decisions for Investors

• Investors should recognize that despite diversification efforts, LLY's near-term performance is overwhelmingly tied to its GLP-1 segment, making the upcoming Q2 sales figures for Mounjaro and Zepbound critical indicators to watch against model estimates of $4.46 billion and $3.09 billion, respectively.
• Given the stock's premium valuation at 29.45 times forward earnings and its Zacks #4 (Sell) rating, investors should weigh the company's strong growth narrative against the significant valuation risk and potential for near-term volatility.
• For a longer-term thesis, monitor the growth trajectory of the non-obesity portfolio, particularly Verzenio and Taltz, as their continued double-digit expansion is a key factor in de-risking the company from its heavy reliance on GLP-1 products.